Advertisement

FDAMA 114

21st Century Cures and Off-Label Promotion Benefit HEOR and Drug Safety

C T2023-11-15T17:41:29-05:00June 4th, 2015|Categories: Blog, HEOR Feature|Tags: 21st Century Cures, Adverse Events, FDA, FDAMA 114, Health Economic Models, Health informatics, tHEORetically Speaking, transparency|

By Jim Davis As my writing for the AdverseEvents Blog can attest, I’m in favor of data transparency. [...]

Playing in the Real World Evidence Sandbox: Sharing, Teamwork, and Transparency

C T2023-11-15T17:45:22-05:00November 19th, 2014|Categories: Blog, HEOR Feature|Tags: Allan Korn, Blue Cross and Blue Shield, clinical research, FDAMA 114, HE-Xpo, health care, Healtheconomics.com, HEOR, HExpo_RWE, late phase research, market access, Nathan White, Patients, Patti Peeples, payers, pharmaceutical, pricing, real world evidence, RWE, tHEORetically Speaking, virtual conferences|

Is just playing in the same sandbox together an example of Real World Evidence (RWE) collaboration? Not really. So how [...]